While Alzheimer's disease is the most common type of dementia, there's another variation that is also relatively prevalent.

NOVEL research proposes a shift from clinical to biological definitions for Parkinson’s disease (PD) and dementia with Lewy ...

Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials. Cognition Therapeutics, Inc. announced promising topline ...

Lewy body dementia (LBD) is a progressive brain disorder that affects thinking, movement, and behavior. It is the second most ...

Detailed data will be presented at the International Lewy Body Dementia Conference (ILBDC) in January 2025.

While Alzheimer’s disease is the most common type of dementia, there’s another variation that is also relatively prevalent. Lewy body dementia (LBD) affects more than 1 million people in the US.

Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body ...

(NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER’ study demonstrating CT1812 produced ...